These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18510173)

  • 1. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.
    Chu Z; Chen JS; Liau CT; Wang HM; Lin YC; Yang MH; Chen PM; Gardner ER; Figg WD; Sparreboom A
    Anticancer Drugs; 2008 Mar; 19(3):275-81. PubMed ID: 18510173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
    Malingré MM; Beijnen JH; Rosing H; Koopman FJ; van Tellingen O; Duchin K; Ten Bokkel Huinink WW; Swart M; Lieverst J; Schellens JH
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):347-54. PubMed ID: 11345652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
    Gelderblom H; Mross K; ten Tije AJ; Behringer D; Mielke S; van Zomeren DM; Verweij J; Sparreboom A
    J Clin Oncol; 2002 Jan; 20(2):574-81. PubMed ID: 11786588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
    Meerum Terwogt JM; Malingré MM; Beijnen JH; ten Bokkel Huinink WW; Rosing H; Koopman FJ; van Tellingen O; Swart M; Schellens JH
    Clin Cancer Res; 1999 Nov; 5(11):3379-84. PubMed ID: 10589748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
    Veltkamp SA; Alderden-Los C; Sharma A; Rosing H; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):43-50. PubMed ID: 16680462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
    Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.
    Malingré MM; Schellens JH; van Tellingen O; Rosing H; Koopman FJ; Duchin K; Huinink WW; Swart M; Beijnen JH
    Anticancer Drugs; 2000 Nov; 11(10):813-20. PubMed ID: 11142688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
    de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
    Br J Clin Pharmacol; 2005 Mar; 59(3):325-34. PubMed ID: 15752379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
    Malingré MM; Beijnen JH; Rosing H; Koopman FJ; Jewell RC; Paul EM; Ten Bokkel Huinink WW; Schellens JH
    Br J Cancer; 2001 Jan; 84(1):42-7. PubMed ID: 11139311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel.
    Malingré MM; Ten Bokkel Huinink WW; Duchin K; Schellens JH; Beijnen JH
    Anticancer Drugs; 2001 Aug; 12(7):591-3. PubMed ID: 11487715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography/tandem mass spectrometry.
    Gardner ER; Liau CT; Chu ZE; Figg WD; Sparreboom A
    Rapid Commun Mass Spectrom; 2006; 20(14):2170-4. PubMed ID: 16779869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Gelderblom H; Verweij J; van Zomeren DM; Buijs D; Ouwens L; Nooter K; Stoter G; Sparreboom A
    Clin Cancer Res; 2002 Apr; 8(4):1237-41. PubMed ID: 11948138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.
    van Asperen J; van Tellingen O; van der Valk MA; Rozenhart M; Beijnen JH
    Clin Cancer Res; 1998 Oct; 4(10):2293-7. PubMed ID: 9796957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.
    van Zuylen L; Karlsson MO; Verweij J; Brouwer E; de Bruijn P; Nooter K; Stoter G; Sparreboom A
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):309-18. PubMed ID: 11345647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
    Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
    Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
    van Zuylen L; Gianni L; Verweij J; Mross K; Brouwer E; Loos WJ; Sparreboom A
    Anticancer Drugs; 2000 Jun; 11(5):331-7. PubMed ID: 10912949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of oral paclitaxel.
    Malingré MM; Terwogt JM; Beijnen JH; Rosing H; Koopman FJ; van Tellingen O; Duchin K; Huinink WW; Swart M; Lieverst J; Schellens JH
    J Clin Oncol; 2000 Jun; 18(12):2468-75. PubMed ID: 10856107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
    Scripture CD; Szebeni J; Loos WJ; Figg WD; Sparreboom A
    Cancer Biol Ther; 2005 May; 4(5):555-60. PubMed ID: 15917657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
    Sparreboom A; Verweij J; van der Burg ME; Loos WJ; Brouwer E; Viganò L; Locatelli A; de Vos AI; Nooter K; Stoter G; Gianni L
    Clin Cancer Res; 1998 Aug; 4(8):1937-42. PubMed ID: 9717822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.